The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2024 | The evolution of lung cancer treatment toward personalization
Samreen Ahmed, University Hospitals of Leicester, UK, discusses the evolving landscape of lung cancer treatment, particularly in the curative space. The integration of neoadjuvant chemotherapy and immunotherapy before surgery marks a significant advancement, enabling systemic therapies alongside surgical interventions. Prof. Ahmed highlights the imminent emergence of perioperative treatments, encompassing neoadjuvant surgery and adjuvant therapy. She emphasizes the importance of personalized approaches in determining the necessity and extent of postoperative treatments. Additionally, she delves into the potential of circulating tumor DNA (ctDNA) as a tool for early detection and treatment decision-making, both in advanced and early-stage disease. These insights shed light on the ongoing efforts to tailor lung cancer management for individual patients. This interview took place at the BTOG 2024 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
